RadarScreen
RadarScreen, a novel yeast-based screening system allowing rapid and cost-effective identification of genotoxic compounds in early stage drug discovery.
Potential DNA damaging compounds can be detected in a high-throughput cellular screen using RadarScreen, a method developed by reMYND and based on the sensitivity of a reporter gene to DNA damage in eukaryotic cells.
reMYND's RadarScreen assay is fully validated and:
- Identifies genotox liabilities of compounds or its metabolites more sensitively, user friendly and cost-effectively than any of the currently available screens of its kind
- Is especially suitable for the identification of clastogenic compounds and highly predictive of in vitro SCE and micronucleus tests
- Allows genotox screening early on in the discovery process
Share
More information
Fill in the form and download a concise overview presentation of reMYND's RadarScreen assay here.
